Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Colony forming units

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    85 result(s) found for: Colony forming units. Displaying page 4 of 5.
    « Previous 1  2  3  4  5  Next»
    EudraCT Number: 2016-004318-82 Sponsor Protocol Number: CTBM100CUS03 Start Date*: 2017-05-15
    Sponsor Name:Novartis Pharmaceuticals Corporation
    Full Title: Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    20.0 100000004862 10021860 Infection Pseudomonas aeruginosa LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-003975-23 Sponsor Protocol Number: IGX1-ENT-XS-16-01 Start Date*: 2020-04-20
    Sponsor Name:Asherman Therapy S.L.U.
    Full Title: Efficacy and safety of autologous, mobilized, non-expanded CD133+ cells to treat Asherman´s Syndrome: A prospective, multi-center, phase I/II clinical trial.
    Medical condition: Asherman's syndrome also known as intrauterine synechiae
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038604 - Reproductive system and breast disorders 10053868 Asherman's syndrome PT
    Population Age: Adults Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-000381-35 Sponsor Protocol Number: OVG 2011/02 Start Date*: 2011-09-26
    Sponsor Name:University of Oxford
    Full Title: Understanding typhoid disease after vaccination: a single centre, randomised, double-blind, placebo-controlled study to evaluate M01ZH09 in a healthy adult challenge model, using Ty21a vaccine as a...
    Medical condition: Active immunisation for the prevention of typhoid infection in healthy adults.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10045275 Typhoid fever PT
    14.0 10021881 - Infections and infestations 10045272 Typhoid LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2020-001076-14 Sponsor Protocol Number: K12-2020 Start Date*: 2020-04-20
    Sponsor Name:Oulu University Hospital, Oulu, Finland [...]
    1. Oulu University Hospital, Oulu, Finland
    2. University of Oulu
    Full Title: Efficacy of Streptococcus salivarius K12 oral probiotic products in preventing acute otitis media: A randomized placebo-controlled trial.
    Medical condition: Acute otitis media
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10033084 Otitis media NOS LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2014-003244-13 Sponsor Protocol Number: D4280C00016 Start Date*: 2015-04-17
    Sponsor Name:Pfizer Inc.
    Full Title: A single blind, randomised, multi-centre, active controlled, trial to evaluate safety, tolerability, pharmacokinetics and efficacy of ceftazidime and avibactam compared with cefepime in children fr...
    Medical condition: Complicated urinary tract infections
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000005053 10046577 Urinary tract infections HLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) GR (Completed) PL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2015-002743-33 Sponsor Protocol Number: Z7224L01 Start Date*: 2017-02-21
    Sponsor Name:Zambon S.p.A.
    Full Title: A double-blind, placebo controlled, multi-centre, clinical trial to investigate the efficacy and safety of 12 months of therapy with inhaled colistimethate sodium in the treatment of subjects with ...
    Medical condition: Non-cystic fibrosis bronchiectasis chronically infected with Pseudomonas aeruginosa
    Disease: Version SOC Term Classification Code Term Level
    21.0 10038738 - Respiratory, thoracic and mediastinal disorders 10006445 Bronchiectasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) DE (Completed) PT (Completed) NL (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-002067-10 Sponsor Protocol Number: MSC-JIA Start Date*: 2014-01-30
    Sponsor Name:University Medical Center Utrecht
    Full Title: Mesenchymal stromal cells for treatment of drug resistant pediatric Juvenile idiopathic arthritis
    Medical condition: juvenile idiopathic arthritis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10028395 - Musculoskeletal and connective tissue disorders 10059176 Juvenile idiopathic arthritis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-005606-22 Sponsor Protocol Number: OC5-DB-01 Start Date*: 2013-07-10
    Sponsor Name:OxThera AB
    Full Title: A Phase 1/2, randomised, placebo-controlled, double-blind, multi-centre study to evaluate the efficacy and safety of OC5 to reduce urinary oxalate in subjects with primary hyperoxaluria
    Medical condition: Primary Hyperoxaluria (PH)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10038359 - Renal and urinary disorders 10020703 Hyperoxaluria PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-002938-23 Sponsor Protocol Number: pro-SWAP104622 Start Date*: 2018-02-06
    Sponsor Name:Radboud University Medical Center
    Full Title: The effect of rectal swab culture-guided antimicrobial prophylaxis in men undergoing prostate biopsy on infectious complications and cost of care: A randomized controlled trial in the Netherlands.
    Medical condition: Antimicrobial prophylaxis for patients undergoing prostate biopsy concerning infectious complications.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    20.0 10042613 - Surgical and medical procedures 10064736 Antibiotic prophylaxis PT
    20.1 10022891 - Investigations 10004857 Biopsy prostate PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004899-18 Sponsor Protocol Number: LUSPLUS Start Date*: 2021-09-17
    Sponsor Name:GWT-TUD GmbH
    Full Title: A phase IIIb, open-label, single arm study to evaluate the efficacy and safety of luspatercept in patients with lower-risk MDS and ring-sideroblastic phenotype (MDS-RS)
    Medical condition: Lower-risk myelodysplastic syndrome with ring-sideroblastic phenotype (MDS-RS)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028534 Myelodysplastic syndrome NOS LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068361 MDS LLT
    20.0 10005329 - Blood and lymphatic system disorders 10050910 Bone marrow disorder NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) AT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002543-41 Sponsor Protocol Number: 64041757LUC2002 Start Date*: 2018-02-20
    Sponsor Name:Janssen-Cilag International NV
    Full Title: An Open-label Randomized Phase 1b/2 Study of the Efficacy and Safety of JNJ-64041757, a Live Attenuated Listeria monocytogenes Immunotherapy, in Combination with Nivolumab Versus Nivolumab Monother...
    Medical condition: Advanced adenocarcinoma of the lung
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10001164 Adenocarcinoma lung stage III LLT
    20.0 100000004864 10001165 Adenocarcinoma lung stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-002328-14 Sponsor Protocol Number: OC3-DB-01 Start Date*: 2008-01-10
    Sponsor Name:OxThera Inc.
    Full Title: A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multi-center, International Study to Evaluate the Efficacy and Safety of Oxabact(TM) to Reduce Urinary Oxalate in Subjects with Primary H...
    Medical condition: primary hyperoxaluria
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020703 Hyperoxaluria LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (Completed) NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-004161-68 Sponsor Protocol Number: AG013-ODOM-201 Start Date*: 2018-10-31
    Sponsor Name:Oragenics, Inc.
    Full Title: A Phase 2, multi-center, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of topically-applied AG013 for the attenuation of oral mucositis in subjects with cance...
    Medical condition: Oral mucositis (OM) induced by chemoradiation therapy (CRT) used for the treatment of head and neck cancers (HNC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10028130 Mucositis oral LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Prematurely Ended) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2013-004556-38 Sponsor Protocol Number: TP-434-010 Start Date*: 2014-02-24
    Sponsor Name:Tetraphase Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of Eravacycline Compared with Levofloxacin in Complicated Urinary Tract Infections
    Medical condition: Complicated urinary tract Infections
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004862 10046576 Urinary tract infection, site not specified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) IT (Completed) EE (Completed) CZ (Completed) LV (Completed) GR (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2018-003576-12 Sponsor Protocol Number: OC5-OL-02 Start Date*: 2019-01-23
    Sponsor Name:OxThera Intellectual Property AB
    Full Title: An open-label single-arm treatment extension study to evaluate the long-term efficacy and safety of Oxabact® for patients with primary hyperoxaluria who completed study OC5-DB-02
    Medical condition: Primary Hyperoxaluria (PH)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10020702 Hyperoxalemia LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (GB - no longer in EU/EEA) ES (Prematurely Ended) BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-004558-13 Sponsor Protocol Number: Z7224L02 Start Date*: 2017-05-30
    Sponsor Name:Zambon S.p.A.
    Full Title: A double-blind, placebo controlled, multicentre, clinical trial to investigate the efficacy and safety of 12 months of therapy with inhaled Promixin® (colistimethate sodium) in the treatment of sub...
    Medical condition: Non-cystic fibrosis bronchiectasis chronically infected with Pseudomonas aeruginosa
    Disease: Version SOC Term Classification Code Term Level
    19.1 10038738 - Respiratory, thoracic and mediastinal disorders 10006445 Bronchiectasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) PL (Completed) DE (Completed) PT (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-001280-24 Sponsor Protocol Number: VE202-002 Start Date*: 2022-07-20
    Sponsor Name:Vedanta Biosciences, Inc.
    Full Title: Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of VE202 in Patients with Mild-to-Moderate Ulcerative Colitis
    Medical condition: Mild-to-moderate ulcerative colitis (UC)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) HU (Trial now transitioned) LT (Trial now transitioned) BG (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-002121-30 Sponsor Protocol Number: 1704R2133 Start Date*: 2020-04-17
    Sponsor Name:Shionogi B.V.
    Full Title: An Open-label Study with a Nonrandomized Single-dose Phase in Subjects with Suspected or Confirmed Aerobic Gram-negative Bacterial Infections followed by a Randomized, Multiple-dose, Active-control...
    Medical condition: Single dose: Pneumonia, cUTI, complicated intra-abdominal infections [cIAI], hospital acquired bacterial pneumonia [HABP]/ventilator-associated bacterial pneumonia [VABP], and sepsis or bloodstream...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    20.0 10021881 - Infections and infestations 10076918 Hospital acquired pneumonia LLT
    20.1 10021881 - Infections and infestations 10065153 Ventilator associated pneumonia LLT
    20.0 10021881 - Infections and infestations 10046577 Urinary tract infections HLT
    20.0 10021881 - Infections and infestations 10040047 Sepsis PT
    24.1 10021881 - Infections and infestations 10003997 Bacteraemia PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: LT (Completed) GR (Completed) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001009-98 Sponsor Protocol Number: allo-APZ2-EB-II-01 Start Date*: 2019-03-01
    Sponsor Name:RHEACELL GmbH & Co. KG
    Full Title: An interventional, multicenter, single arm, phase I/IIa clinical trial to investigate the efficacy and safety of allo-APZ2-EB on epidermolysis bullosa (EB)
    Medical condition: Recessive dystrophic epidermolysis bullosa (RDEB)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10014989 Epidermolysis bullosa PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) GB (GB - no longer in EU/EEA) FR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-019181-91 Sponsor Protocol Number: EAURF2008-01 Start Date*: 2013-05-24
    Sponsor Name:EAU Foundation for Urological Research
    Full Title: Treatment of High Grade Non-Muscle Invasive Urothelial Carcinoma of the Bladder by Standard Number and Dose of Intravesical BCG Instillations Versus Reduced Number of Intravesical Instillations wi...
    Medical condition: Non muscle invasive bladder cancer after transurethral resection of the Bladder Tumor (TURT).
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FR (Prematurely Ended) BE (Completed) ES (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 27 20:05:03 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA